Be Bio raises $92M to advance hemophilia B treatment BE-101
Be Biopharma has raised $92 million in series C financing to support the first-in-human Phase 1/2 trial of BE-101,…
Articles by Andrea Lobo, PhD
Liver cancer seen as common risk for men with hemophilia and HIV
Men with hemophilia and infected with the human immunodeficiency virus (HIV) are at a high risk of developing certain…
IND-enabling studies for hemophilia A gene-editing therapy to advance
Metagenomi, which is developing MGX-001, a gene-editing therapy for hemophilia A, is preparing to initiate investigational new drug…
Centessa discontinues development of SerpinPC for hemophilia
Centessa Pharmaceuticals is discontinuing the clinical development of SerpinPC, its experimental under-the-skin therapy for people with hemophilia A…
Hemophilia patients more likely to be infected with SENV: Study
People with hemophilia are more likely to be infected with the SEN virus (SENV), which is associated with blood…
Reimbursement urged in Spain for Hemgenix hemophilia B treatment
The Spanish Interministerial Commission on the Pricing of Medicines, known as CIPM, has issued a positive recommendation for national reimbursement…
Marstacimab recommended for EU approval for hemophilia A and B
Note: This story was updated Oct. 15, 2024, to note results from the subset of patients with inhibitors participating…
No real COVID-19 infection impact seen for hemophilia patients
Having a COVID-19 infection had no significant impact on bleeding episodes, nor on the levels of factor replacement therapy…
MGX-001 gene-editing therapy shows promise in preclinical study
MGX-001, a gene-editing therapy being developed by Metagenomi for hemophilia A, has shown promising safety and durability in…
Hemophilia A, B gene therapies now at Loma Linda University Health
Loma Linda University Health (LLUH) is now offering the gene therapies Hemgenix (etranacogene dezaparvovec) to people with hemophilia B…